Clinical Trials Link
Primary Protocol Team Members
IMPAACT P1112 is an open-label, dose-escalating, phase I multicenter trial to determine the safety and pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS when given to HIV-1 exposed infants. VRC01, VRC01LS, and VRC07-523LS are potent anti-HIV neutralizing monoclonal antibodies. The primary objectives of P1112 are to assess the safety and pharmacokinetic profiles of VRC01 (single dose for Dose Groups 1 and 2; monthly doses for Dose Group 3), VRC01LS (one or two doses for Dose Group 4) and VRC07-523LS (one or two doses for Dose Group 5), all administered subcutaneously.